Joseph J. Lynch

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

47h-index6.7kcitations213works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cardiac electrophysiology and arrhythmias(79), Cardiac Arrhythmias and Treatments(41), Ion channel regulation and function(31), Atrial Fibrillation Management and Outcomes(18), Blood Coagulation and Thrombosis Mechanisms(15)

Publications213 total

Use of Microcomputed Tomography to Measure the Relaxin-induced Expansion of Intrapubic Ligaments in Mice.
PubMed·2017Open Access
Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics
Bioorganic & Medicinal Chemistry Letters·2017· 8 citedOpen Access
Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model
SAGE Open Medicine·2017· 5 citedOpen Access
Martial Arts as Philosophy
2017
Early echocardiographic predictors of outcomes in the mouse transverse aortic constriction heart failure model
Journal of Pharmacological and Toxicological Methods·2016· 14 cited
Treatments for Heart Failure
Elsevier eBooks·2016· 3 cited
Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective<i>N</i>‐methyl‐D‐aspartate receptor antagonist
Pharmacology Research & Perspectives·2015· 41 citedOpen Access
De-risking the effect of CGRP receptor antagonists on coronary blood flow and systemic hemodynamics in nonhuman primates
Journal of Pharmacological and Toxicological Methods·2014· 1 cited
The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation
Cardiovascular Research·2013· 125 citedOpen Access
Comparison of the Intrinsic Vasorelaxant and Inotropic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in Human Isolated Vascular and Cardiac Tissues
Journal of Cardiovascular Pharmacology·2012· 10 cited
MK-0448, a Specific Kv1.5 Inhibitor
Circulation Arrhythmia and Electrophysiology·2012· 47 cited
Animals as Biotechnology: Ethics, Sustainability and Critical Animal Studies
Journal of Animal Ethics·2012· 52 cited
Use of non-human primate models to enable early investigational cardiovascular de-risking
Journal of Pharmacological and Toxicological Methods·2012
Confessions of a Tattooed Buddhist Philosopher
2012· 1 cited
Rate-Dependent Effects of Vernakalant in the Isolated Non-Remodeled Canine Left Atria Are Primarily Due to Block of the Sodium Channel
Circulation Arrhythmia and Electrophysiology·2012· 47 citedOpen Access
Nature Red in Tooth and Claw: Theism and the Problem of Animal Suffering, by Michael Murray
Faith and Philosophy·2012· 1 cited
Suffering, Spirituality, and Sensuality
2011
Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations
Heart Rhythm·2011· 21 citedOpen Access
God, animals and zombies
Repositorio institucional da Universidade de Santiago de Compostela (University of Santiago de Compostela)·2011· 19 citedOpen Access
Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitors
Bioorganic & Medicinal Chemistry Letters·2010· 6 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Joseph P. Vacca(9), Jacquelynn J. Cook(9), Elizabeth Baskin(8), Maria T. Stranieri(8), Gary L. Stump(8), Audrey A. Wallace(7), George D. Hartman(7), Sidney D. Lewis(7), Elizabeth A. Lyle(7), Marie A. Holahan(7), Stephen J. Gardell(7), David A. Claremon(7), Joseph J. Salata(6), Bobby J. Lucas(6), Christopher P. Regan(6), Harold G. Selnick(6), Gary R. Sitko(5), Julie A. Krueger(5), Adel M. Naylor-Olsen(5), I‐Wu Chen(5)